First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].

Arthritis Res Ther · 2006 · PMC1526611 · PMID 16469112

Europe PMC DOI

hedged sentences

0.0010

closest p · 0.0× alpha

0.4210

boldest claim

The sentences

highly significantP < 0.001actually significant

For both active treatments, a highly significant difference relative to placebo was apparent (lumiracoxib, P < 0.001; celecoxib, P = 0.001); however, there was no difference between active treatment groups ( P = 0.100).

also in 132,142 other papers

failed to achieve significanceP = 0.056so close (0.05 < p ≤ 0.1)

WOMACTM total and subscales improved for both active treatments versus placebo except for difficulty in performing daily activities, for which celecoxib just failed to achieve significance ( P = 0.056).

also in 299 other papers

difference was apparentP = 0.421not close (p > 0.1)

However, no significant difference was apparent between the active treatment groups at study end (estimated difference for lumiracoxib versus celecoxib in APID: 2.0 mm, 95% CI -2.94 to +7.01 mm; P = 0.421).

also in 830 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.